Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621152 · ClinicalTrials.gov registry record · NA
PRevention of Acute Kidney Injury Initiated With Electronic Surveillance Enhancement
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 2,266
- Enrollment target
NCT01621152: Completed NA study, sponsored by Mayo Clinic.
NCT01621152 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 2,266 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01621152, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,266 participants
- Enrollment target
Study Summary
Introduction: Acute kidney injury (AKI) increases mortality, hospital cost, and rate of progression toward end stage kidney disease 1-4. Early diagnosis and management of AKI is known to improve the above mentioned outcomes. Hypothesis: the investigators will design and validate an electronic surveillance tool to screen all the ICU admissions for the earlier, more efficient diagnosis of AKI and as a result improve the outcome of AKI in ICU patients. Methods: the investigators plan to use the patient database, and AKIN (AKI network) definition to design an electronic alert system to allow clinicians discover patients who develop AKI. Then a randomized clinical trial will be conducted to compare earlier intervention (based on Kidney Disease: Improving Global Outcomes \[KDIGO\] guidelines) initiated by AKI sniffer alert to the conventional management provided by primary physician in ICU.
Primary Outcome
The Acute Kidney Injury Network staging system is based on data indicating that a small change in serum creatinine influences outcome. Increases in serum creatinine or decreased urine output indicate greater kidney injury, with the stage ranging from 1 to 3. The higher the number, the greater the kidney injury.
Interventions
- OTHER Conventional management arm
- OTHER AKI sniffer instigated AKI management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,266 participants |
| Start Date | 2012-06 |
| Est. Completion | 2021-10-19 |
| Phase | NA |
What the finished NCT01621152 record still lists
NCT01621152 is an interventional study that assigns participants to a tested intervention. Its 2,266 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% higher).
The record links to 0 conditions, and to 2 interventions - of which Conventional management arm is the first listed.
NCT01621152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01621152 about?
NCT01621152 is a clinical study titled "PRevention of Acute Kidney Injury Initiated With Electronic Surveillance Enhancement". Introduction: Acute kidney injury (AKI) increases mortality, hospital cost, and rate of progression toward end stage kidney disease 1-4. Early diagnosis and management of AKI is known to improve the above mentioned outcomes. Hypothesis: the investigators will design and validate an electronic surve...
What is the current status of trial NCT01621152?
This trial is currently completed. It is a NA study. The enrollment target is 2,266 participants. The study started on 2012-06. Estimated completion is 2021-10-19.
What interventions are being tested in trial NCT01621152?
The interventions under investigation include: Conventional management arm (OTHER), AKI sniffer instigated AKI management (OTHER).
Who is sponsoring clinical trial NCT01621152?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01621152's enrollment target sits among peer trials
2,266 48th of 2000 higher than 1,953 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia